Method of treatment of inflamed tissues

• US 5,356,633 A
• Filed: 10/07/1992
• Issued: 10/18/1994
• Est. Priority Date: 10/20/1989
• Status: Expired due to Term

• Current Assignee: Liposome Technology, Inc.
• Original Assignee: Liposome Technology, Inc.
• Inventors: Martin, Francis J., Huang, Shi K., Woodle, Martin C.
• Primary Examiner(s): Page, Thurman K.
• Assistant Examiner(s): Spear, James M.
• Application Number:
  US07/958,100
• Time in Patent Office: 741 Days
• Field of Search: 424/450, 424/423, 424/424
• US Class Current: 424/450
• CPC Class Codes: A61K 9/1271 Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers liposome as conjugate A61K47/6911
• CPC Class Codes: C07F 9/5537 the heteroring containing the structure -C(=O)-N-C(=O)- (both carbon atoms belong to the heteroring)

Abstract

A method of and composition for concentrating a therapeutic agent in an inflamed dermal region are disclosed. The composition, which is also used in the method, is a liposomal composition. The liposomes contain the therapeutic agent in entrapped form and are composed of vesicle-forming lipids including a vesicle-forming lipid derivatized with hydrophilic biocompatible polymer. After intravenous administration, the liposomes are taken up by the inflamed region within 24-48 hours, for site-specific release of entrapped compound into the inflamed region.

Claims

1. A method of concentrating a therapeutic compound in an inflamed dermal region in a subject, comprising

administering to the subject, by parenteral injection, a composition of liposomes (i) composed of vesicle-forming lipids including an amphipathic vesicle-forming lipid derivatized with a hydrophilic biocompatible polymer selected from the group consisting of a polyethylene glycol having a molecular weight between about 300 and 5,000 daltons, polyglycolic acid (PGA), polylactic acid (PLA), a copolymer of PGA and PLA, and polyvinyl alcohol (ii) having a selected mean particle diameter in the size range between about 0.07-0.20 microns, and (iii) containing in liposome-entrapped form, a therapeutic compound effective against the source of the inflammation, and

by said injecting, concentrating the liposomes in the inflamed region, thereby to concentrate liposome-entrapped compound at the site of inflammation.

2. The method of claim 1, wherein the liposome-entrapped compound is a steroidal anti-inflammatory compound.

3. The method of claim 2, wherein the anti-inflammatory compound is selected from the group consisting of prednisone, methylprednisolone, paramethazone, 11-fludrocortisol, triamcinolone, betamethasone and dexamethasone.

4. The method of claim 2, wherein the antiinflammatory compound is beclomethasone.

5. The method of claim 1, wherein the dermal inflammation is a psoriatic dermal inflammation, and the liposome-entrapped compound is selected from the group consisting of steroidal antiinflammatory agents, nonsteroidal antiinflammatory agents, immunosuppressant agents, methotrexate, azaribine, etretinate, anthralin, and psoralins.

6. The method of claim 5, wherein the immunosuppressant agent is cyclosporine.